Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy

could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed. The view comes after Sarepta said late Tuesday the Food and Drug Administration won't hold an advisory committee meeting to discuss its gene therapy, SRPT-9001. These…#sarepta #fda #needham #gilblum #marketsmithcom #duchenne #blum #novavaxstockplummets
Source: Reuters: Health - Category: Consumer Health News Source Type: news